tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

PCVX Stock Latest News

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Press ReleasesVaxcyte to Present at the 2024 Cantor Global Healthcare Conference
8d ago
PCVX
Vaxcyte price target raised to $163 from $113 at Mizuho
PremiumThe Fly
Vaxcyte price target raised to $163 from $113 at Mizuho
10d ago
PCVX
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
PremiumPress Releases
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
13d ago
PCVX
Vaxcyte 10.2M share Secondary priced at $103.00
PremiumThe Fly
Vaxcyte 10.2M share Secondary priced at $103.00
15d ago
PCVX
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
PremiumPress Releases
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
15d ago
PCVX
Vaxcyte price target raised to $130 from $101 at Guggenheim
PremiumThe FlyVaxcyte price target raised to $130 from $101 at Guggenheim
16d ago
PCVX
Vaxcyte price target raised to $140 from $101 at BofA
Premium
The Fly
Vaxcyte price target raised to $140 from $101 at BofA
16d ago
PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Premium
Press Releases
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
16d ago
PCVX
Vaxcyte announces $1B common stock and warrants offering
PremiumThe Fly
Vaxcyte announces $1B common stock and warrants offering
16d ago
PCVX
Vaxcyte price target raised to $153 at Leerink after VAX-31 ‘home run’
PremiumThe Fly
Vaxcyte price target raised to $153 at Leerink after VAX-31 ‘home run’
16d ago
PCVX
Needham ups Vaxcyte target to $140 after ‘best-case scenario’ data
PremiumThe Fly
Needham ups Vaxcyte target to $140 after ‘best-case scenario’ data
16d ago
PCVX
Vaxcyte price target raised to $140 from $95 at Needham
PremiumThe Fly
Vaxcyte price target raised to $140 from $95 at Needham
16d ago
PCVX
ESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
PremiumThe FlyESPN goes dark on DirecTV, Harris to oppose Nippon-U.S. Steel deal: Morning Buzz
16d ago
H
T
Vaxcyte price target raised to $160 from $98 at BTIG
Premium
The Fly
Vaxcyte price target raised to $160 from $98 at BTIG
16d ago
PCVX
Morning Movers: U.S. Steel drops after VP Harris opposes sale to Nippon
Premium
The Fly
Morning Movers: U.S. Steel drops after VP Harris opposes sale to Nippon
17d ago
U
X
Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial
PremiumCompany Announcements
Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial
17d ago
8K
PCVX
Vaxcyte reports data from study of VAX-31 vaccine candidate in adults 50+
PremiumThe Fly
Vaxcyte reports data from study of VAX-31 vaccine candidate in adults 50+
17d ago
PCVX
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
PremiumPress Releases
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
17d ago
PCVX
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
PremiumPress Releases
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
17d ago
PCVX
Vaxcyte reports Q2 EPS ($1.10), consensus (98c)
PremiumThe FlyVaxcyte reports Q2 EPS ($1.10), consensus (98c)
1M ago
PCVX
Vaxcyte Appoints John Furey as New Independent Board Director
Premium
Company Announcements
Vaxcyte Appoints John Furey as New Independent Board Director
3M ago
8K
PCVX
Vaxcyte Appoints John Furey to Board of Directors
Premium
Press Releases
Vaxcyte Appoints John Furey to Board of Directors
3M ago
PCVX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >